KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Long-Term Deferred Tax: 2020-2025

Historic Long-Term Deferred Tax for Pacira BioSciences (PCRX) over the last 5 years, with Sep 2025 value amounting to $120.2 million.

  • Pacira BioSciences' Long-Term Deferred Tax fell 10.32% to $120.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.2 million, marking a year-over-year decrease of 10.32%. This contributed to the annual value of $130.4 million for FY2024, which is 9.77% down from last year.
  • According to the latest figures from Q3 2025, Pacira BioSciences' Long-Term Deferred Tax is $120.2 million, which was down 6.30% from $128.3 million recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' Long-Term Deferred Tax peaked at $169.3 million during Q1 2022, and registered a low of $93.3 million during Q3 2021.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $135.1 million (2024), whereas its average is $139.8 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first skyrocketed by 69.52% in 2022, then fell by 15.82% in 2024.
  • Quarterly analysis of 5 years shows Pacira BioSciences' Long-Term Deferred Tax stood at $153.4 million in 2021, then climbed by 4.53% to $160.3 million in 2022, then decreased by 9.87% to $144.5 million in 2023, then dropped by 9.77% to $130.4 million in 2024, then declined by 10.32% to $120.2 million in 2025.
  • Its Long-Term Deferred Tax was $120.2 million in Q3 2025, compared to $128.3 million in Q2 2025 and $129.0 million in Q1 2025.